/LYRA
LYRA Stock - Lyra Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$3.60-3.23%
$0.12 (-3.23%) • Dec 19
30
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.SELL
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-86.1%upside
Target: $0.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LYRA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.56 – $3.64
TARGET (TP)$0.50
STOP LOSS$3.31
RISK/REWARD1:-10.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.01
52W High$37.50
52W Low$2.84
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.53M | $1.56M | $1.36M | $285,000 | N/A |
| Gross Profit | $1.53M | $1.56M | $1.36M | $-29,409,000 | $-12,522,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | -10318.9% | N/A |
| Operating Income | $-96,348,000 | $-67,120,000 | $-56,306,000 | $-43,615,000 | $-22,209,000 |
| Net Income | $-93,435,000 | $-62,680,000 | $-55,278,000 | $-43,513,000 | $-22,127,000 |
| Net Margin | -6090.9% | -4023.1% | -4055.6% | -15267.7% | N/A |
| EPS | $-1.43 | $-1.26 | $-1.83 | $-3.35 | $-2.59 |
Company Overview
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
40%
Hold / Neutral
2
40%
Sell / Underperform
1
20%
Analyst Consensus🔴 Bearish
2 Bullish3 Neutral/Bearish
Price Targets
$9
Average Target
↑ 147.2% Upside
Now
$1
Low
$9
Average
$15
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 7th 2024 | H.C. Wainwright | Downgrade | Neutral | $2← $12 |
| May 7th 2024 | Jefferies | Downgrade | Hold | $0.5← $10 |
| May 7th 2024 | BofA Securities | Downgrade | Underperform | - |
| May 6th 2024 | William Blair | Downgrade | Market Perform | - |
| October 6th 2023 | BTIG Research | Resumed | Buy | $15 |
| August 31st 2023 | H.C. Wainwright | Initiation | Buy | $12 |
| May 24th 2022 | Cantor Fitzgerald | Initiation | Overweight | $15 |
Earnings History & Surprises
LYRABeat Rate
61%
Last 18 quarters
Avg Surprise
+3.3%
EPS vs Estimate
Beats / Misses
11/7
Last 12 quarters
Latest EPS
$-3.38
Q4 2025
EPS Surprise History
Q1 24
+33.3%
$-0.22vs$-0.33
Q2 24
-34.6%
$-0.35vs$-0.26
Q3 24
+14.7%
$-0.29vs$-0.34
Q4 24
+21.7%
$-0.18vs$-0.23
Q1 25
-23.1%
$-0.16vs$-0.13
Q2 25
+20.0%
$-6.00vs$-7.50
Q3 25
+4.8%
$-5.51vs$-5.79
Q4 25
+43.5%
$-3.38vs$-5.98
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-1.24 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-5.98 | $-3.38 | +43.5% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-5.79 | $-5.51 | +4.8% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-7.50 | $-6.00 | +20.0% | ✓ BEAT |
Q1 2025 | Mar 13, 2025 | $-0.13 | $-0.16 | -23.1% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.23 | $-0.18 | +21.7% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.34 | $-0.29 | +14.7% | ✓ BEAT |
Q2 2024 | Apr 30, 2024 | $-0.26 | $-0.35 | -34.6% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.33 | $-0.22 | +33.3% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.33 | $-0.27 | +18.2% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.44 | $-0.33 | +25.0% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-0.36 | $-0.44 | -22.2% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | $-0.42 | $-0.36 | +14.3% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.42 | $-0.40 | +4.8% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.34 | $-0.43 | -26.5% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.92 | $-0.54 | +41.3% | ✓ BEAT |
Q1 2022 | Mar 9, 2022 | $-0.82 | $-1.05 | -28.0% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.78 | $-0.85 | -9.0% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.61 | $-0.85 | -39.3% | ✗ MISS |
Latest News
Lyra Therapeutics Q3 EPS $(3.38) Beats $(5.25) Estimate, Sales $25.000K Miss $195.000K Estimate
➖ NeutralBenzinga•Nov 12, 2025, 09:37 PM
Lyra Therapeutics Outlines Clinical Plan For LYR-210 Following FDA Meeting And Announces ENLIGHTEN 2 Late-Breaking Oral Presentation
📈 PositiveBenzinga•Oct 6, 2025, 11:08 AM
Lyra Therapeutics Posts 85% Q2 Loss Drop
📉 NegativeThe Motley Fool•Aug 13, 2025, 02:49 AM
Lyra Therapeutics to raise up to $15M via registered direct offering and concurrent private placement, stock falls 22%
📉 NegativeSeeking Alpha•Jun 27, 2025, 12:42 PM
Microcap Lyra Therapeutics surges 376% on phase 3 rhinosinusitis data
📈 PositiveSeeking Alpha•Jun 2, 2025, 07:46 PM
Frequently Asked Questions about LYRA
What is LYRA's current stock price?
Lyra Therapeutics, Inc. (LYRA) is currently trading at $3.60 per share. The stock has moved -3.23% today.
What is the analyst price target for LYRA?
The average analyst price target for LYRA is $0.50, based on 1 analyst.
What sector is Lyra Therapeutics, Inc. in?
Lyra Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LYRA's market cap?
Lyra Therapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does LYRA pay dividends?
No, Lyra Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAEON
AEON Biopharma, Inc.
$1.08
Mkt Cap: $0.0B
APVO
Aptevo Therapeutics Inc.
$1.07
Mkt Cap: $0.0B
BOLT
Bolt Biotherapeutics, Inc.
$5.16
Mkt Cap: $0.0B
CDIO
Cardio Diagnostics Holdings, Inc.
$3.23
Mkt Cap: $0.0B
CING
Cingulate Inc.
$3.97
Mkt Cap: $0.0B
CLRB
Cellectar Biosciences, Inc.
$2.68
Mkt Cap: $0.0B
GLTO
Galecto, Inc.
$27.17
Mkt Cap: $0.0B
HCWB
HCW Biologics Inc.
$1.57
Mkt Cap: $0.0B
INAB
IN8bio, Inc.
$1.21
Mkt Cap: $0.0B
RNAZ
TransCode Therapeutics, Inc.
$7.92
Mkt Cap: $0.0B
Explore stocks similar to LYRA for comparison